Evidence map›Paper›PMID 41322987›Full record

ArticleFrontiers in cellular and infection microbiology2025

Sars-Cov-2 spike protein and plasma from COVID-19 patients induce extracellular traps by myeloid-derived suppressor cells.

Germana Grassi, Simona Gili, Rita Casetti, Zulema Antonia Percario, Nicola Tumino, Paola Vacca, Harpreet Kaur Lamsira, Roberta Nardacci, Stefania Notari, Veronica Bordoni and 8 more

Erratum issuedAbstract read
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Germana GrassiCellular Immunology and Pharmacology Laboratory, National Institute for Infectious Diseases Lazzaro Spallanzani, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy.
Simona GiliCellular Immunology and Pharmacology Laboratory, National Institute for Infectious Diseases Lazzaro Spallanzani, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy.
Rita CasettiCellular Immunology and Pharmacology Laboratory, National Institute for Infectious Diseases Lazzaro Spallanzani, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy.
Zulema Antonia PercarioMolecular Virology and Antimicrobial Immunity Laboratory, Department of Science, Roma Tre University, Rome, Italy.
Nicola TuminoImmunology Research Area, Innate Lymphoid Cells Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Bambino Gesù Children's Hospital, Rome, Italy.
Paola VaccaImmunology Research Area, Innate Lymphoid Cells Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Bambino Gesù Children's Hospital, Rome, Italy.
Harpreet Kaur LamsiraDepartmental Faculty of Medicine, Saint Camillus International University of Health Sciences, Rome, Italy.
Roberta NardacciDepartmental Faculty of Medicine, Saint Camillus International University of Health Sciences, Rome, Italy.
Stefania NotariCellular Immunology and Pharmacology Laboratory, National Institute for Infectious Diseases Lazzaro Spallanzani, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy.
Veronica BordoniOncoematologia e Officina Farmaceutica, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Bambino Gesù Children's Hospital, Rome, Italy.
Eleonora CiminiCellular Immunology and Pharmacology Laboratory, National Institute for Infectious Diseases Lazzaro Spallanzani, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy.
Flavia CristofanelliCellular Immunology and Pharmacology Laboratory, National Institute for Infectious Diseases Lazzaro Spallanzani, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy.
Dorotea RubinoClinical Division, National Institute for Infectious Diseases Lazzaro Spallanzani, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy.
Francesca NoniniClinical Division, National Institute for Infectious Diseases Lazzaro Spallanzani, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy.
Elisabetta AffabrisMolecular Virology and Antimicrobial Immunity Laboratory, Department of Science, Roma Tre University, Rome, Italy.
Luisa MarchioniClinical Division, National Institute for Infectious Diseases Lazzaro Spallanzani, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy.
Chiara AgratiDepartmental Faculty of Medicine, Saint Camillus International University of Health Sciences, Rome, Italy.
Alessandra SacchiMolecular Virology and Antimicrobial Immunity Laboratory, Department of Science, Roma Tre University, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Polymorphonuclear-myeloid-derived suppressor cells (PMN-MDSC) are elevated in COVID-19 patients, playing a crucial role in suppressing the SARS-CoV-2 specific T-cell response and serving as an early marker for disease progression. In this study, we investigated the involvement of PMN-MDSC from COVID-19 patients in the formation of extracellular traps (ET). Methods: Fifty RT-PCR-confirmed severe COVID-19 patients admitted to the ICU and ten healthy donors were enrolled. PBMC were isolated from peripheral blood by density gradient centrifugation, and PMN-MDSC frequency was evaluated by flow cytometry. PMN-MDSC were isolated by immunomagnetic separation. ET extrusion was analyzed by immunofluorescence imaging. Apoptosis of pulmonary microvascular endothelial cells cultured with PMN-MDSC was measured by flow cytometry. Results: We found that platelet-rich plasma (PRP) from COVID-19 patients, unlike that from healthy donors, induced ET formation by PMN-MDSC. Furthermore, the PRP-induced ET was found to be independent of Toll-like receptor 4 (TLR4) signaling. Interestingly, the SARS-CoV-2 Spike protein itself can trigger ET formation via a TLR4-dependent pathway. Additionally, PMN-MDSC induced endothelial cell apoptosis through an ET-independent mechanism. Discussion: These findings highlight a previously unrecognized contribution of PMN-MDSCs to the thrombotic complications in severe COVID-19 cases, underscoring their detrimental impact on disease progression.

Indexed as

Extracellular TrapsMyeloid-Derived Suppressor CellsSpike Glycoprotein, CoronavirusAdultAgedAged, 80 and overApoptosisCOVID-19 Nucleic Acid TestingEndothelial CellsFemaleHumansLeukocytes, MononuclearMaleMiddle AgedPlatelet-Rich PlasmaToll-Like Receptor 4Spike Glycoprotein, Coronavirusspike protein, SARS-CoV-2TLR4 protein, humanToll-Like Receptor 4COVID-19extracellular trapsMDSCSARS-CoV-2spike

Identifiers

PMID41322987
PMCPMC12657375

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.